綠庭投資(600695.SH):綠庭科創減持期屆滿 累計減持1.12%股份
格隆匯10月14日丨綠庭投資(600695.SH)公佈,截至本公告日,公司控股股東之一致行動人上海綠庭科創生態科技有限公司(以下簡稱“綠庭科創”)持有公司2892.30萬股非限售流通A股,佔公司總股本的4.07%。
公司於2020年10月14日收到綠庭科創的《股份減持結果告知函》。綠庭科創股份減持計劃時間區間於2020年10月13日屆滿,減持期內通過上海證券交易所集中競價交易系統累計減持公司股份797.13萬股,佔公司總股本的1.12%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.